Provided by Tiger Trade Technology Pte. Ltd.

SELLAS Life Sciences Group Inc.

5.02
-0.2800-5.28%
Volume:3.41M
Turnover:17.35M
Market Cap:903.60M
PE:-20.38
High:5.27
Open:5.07
Low:4.97
Close:5.30
52wk High:6.14
52wk Low:0.9516
Shares:180.00M
Float Shares:179.00M
Volume Ratio:0.41
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2463
EPS(LYR):-0.2463
ROE:-66.88%
ROA:-34.74%
PB:12.75
PE(LYR):-20.38

Loading ...

Sims Group earnings: SLS now core to growth

MotleyFool
·
Yesterday

Sellas Life Sciences files automatic mixed securities shelf

TIPRANKS
·
Mar 21

Sellas Life Sciences Group Inc: Files for Mixed Shelf Offering; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Mar 21

Sellas Life Sciences price target raised to $10 from $7.50 at Alliance Global

TIPRANKS
·
Mar 20

Sellas Life Sciences Group Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 20

SELLAS Life Sciences Gr Q4 EPS $(0.05) Beats $(0.07) Estimate

Benzinga
·
Mar 20

SELLAS Life Sciences 2025 net loss narrows, cash position strengthens

Reuters
·
Mar 20

BRIEF-SELLAS Life Sciences FY Net Income USD -26.863 Million

Reuters
·
Mar 20

Sellas Life Sciences FY Operating Income USD -28.274 Million

THOMSON REUTERS
·
Mar 20

Press Release: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 20

Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million

Reuters
·
Mar 20

Sellas Life Sciences options imply 6.2% move in share price post-earnings

TIPRANKS
·
Mar 20

Canaccord Genuity Reaffirms Their Buy Rating on Solstice Minerals Limited (SLS)

TIPRANKS
·
Mar 19

Sims Scores Upbeat Fiscal 2026 Guidance on Americas JV Strength

MT Newswires Live
·
Mar 19

Guess which ASX 200 stock is jumping 17% on strong FY26 guidance

MotleyFool
·
Mar 18

Sellas Life Sciences to present preclinical SLS009 data at AACR conference

TIPRANKS
·
Mar 18

SELLAS Life Sciences to present SLS009 AML preclinical data at AACR poster session

Reuters
·
Mar 18

Sellas Life Sciences Group Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
Mar 16

SELLAS (SLS): Advancing AML Pipeline, Strengthened Balance Sheet, and Upcoming Catalysts Drive Higher Target and Buy Rating

TIPRANKS
·
Mar 14

Sellas Life Sciences enrolls first patient in 80-patient Phase 2 SLS009 first-line AML trial

Reuters
·
Mar 12